BioMarin Pharmaceuticals BMRN D&A

D&A at other companies

Sarepta Therapeutics, Inc.SRPT

$10.41M-4.0%

PTC TherapeuticsPTCT

$15.41M+113%

Zevra Therapeutics, Inc.ZVRA

$364K-78.0%

Agios PharmaceuticalsAGIO

$1.35M+7.2%

RegenxbioRGNX

$3.76M-3.8%

BridgeBio PharmaBBIO

$1.19M-7.6%

FAQ

What is BioMarin Pharmaceuticals's D&A?

BioMarin Pharmaceuticals (BMRN) reported D&A of $97.64M in Q2 2026.

How has BioMarin Pharmaceuticals's D&A changed year-over-year?

BioMarin Pharmaceuticals's D&A increased by 426.0% year-over-year, from $18.56M to $97.64M.

What is the long-term trend for BioMarin Pharmaceuticals's D&A?

Over 4 years (2021 to 2025), BioMarin Pharmaceuticals's D&A has grown at a -7.4% compound annual growth rate (CAGR), from $108.04M to $79.56M.

What does D&A mean?

Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.